¼¼°èÀÇ ÇコÄÉ¾î µ¥ÀÌÅÍ »óÈ£¿î¿ë¼º ½ÃÀå
Healthcare Data Interoperability
»óǰÄÚµå : 1774897
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 566 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è ÇコÄÉ¾î µ¥ÀÌÅÍ »óÈ£¿î¿ë¼º ½ÃÀåÀº 2030³â±îÁö 131¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 68¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÇコÄÉ¾î µ¥ÀÌÅÍ »óÈ£¿î¿ë¼º ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 11.5%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 131¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ±âÃÊ ·¹º§Àº CAGR 12.1%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 87¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±¸Á¶ ·¹º§ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 9.4%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 19¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 15.6%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÇコÄÉ¾î µ¥ÀÌÅÍ »óÈ£¿î¿ë¼º ½ÃÀåÀº 2024³â¿¡ 19¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 27¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 15.6%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 8.3%¿Í 10.3%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 9.1%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¼¼°è ÇコÄÉ¾î µ¥ÀÌÅÍ »óÈ£¿î¿ë¼º ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

µ¥ÀÌÅÍ »óÈ£¿î¿ë¼ºÀÌ ÇコÄɾîÀÇ °ÔÀÓ Ã¼ÀÎÀú°¡ µÇ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

¼­·Î ´Ù¸¥ Ç÷§Æû°ú ½Ã½ºÅÛ °£¿¡ ÇコÄÉ¾î µ¥ÀÌÅ͸¦ ¿øÈ°ÇÏ°Ô ±³È¯ÇÒ ¼ö ÀÖ´Â ´É·ÂÀº ȯÀÚ °á°ú °³¼±, ºñ¿ë Àý°¨, ¾÷¹« È¿À²¼º Çâ»ó¿¡ ÇʼöÀûÀÎ ¿ä¼ÒÀÔ´Ï´Ù. ÇコÄÉ¾î µ¥ÀÌÅÍ »óÈ£¿î¿ë¼ºÀº ÀüÀÚÀǹ«±â·Ï(EHR), ¿µ»ó ½Ã½ºÅÛ, ¿þ¾î·¯ºí, °Ë»ç Á¤º¸ ½Ã½ºÅÛÀÌ ¼­·Î Åë½ÅÇÒ ¼ö ÀÖµµ·Ï ÇÏ¿© ÀÇ·á Á¦°ø¾÷ü, º¸Çè»ç, ¿¬±¸±â°üÀ» ³Ñ¾î ȯÀÚ µ¥ÀÌÅÍ¿¡ Á¢±ÙÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. »óÈ£¿î¿ë¼ºÀÇ ºÎÁ·Àº Á¾Á¾ Áߺ¹ °Ë»ç, ¿ÀÁø, Ä¡·á Áö¿¬À¸·Î À̾îÁ® ÇùÁø ÀÇ·áÀÇ Å« À庮À¸·Î ÀÛ¿ëÇØ ¿Ô½À´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿Í µ¥ÀÌÅÍ ±â¹Ý ÇコÄɾîÀÇ ºÎ»óÀ¸·Î ½Ç½Ã°£ ÀÇ»ç°áÁ¤°ú ¿¹Ãø ºÐ¼®À» À§Çؼ­´Â ¿øÈ°ÇÑ µ¥ÀÌÅÍ ±³È¯ÀÌ ÇʼöÀûÀÔ´Ï´Ù. ¹Ì±¹ÀÇ 21¼¼±â Ä¡·á¹ý(21st Century Cures Act)°ú À¯·´¿¬ÇÕ(EU)ÀÇ ÀÏ¹Ý µ¥ÀÌÅÍ º¸È£ ±ÔÁ¤(GDPR(EU °³ÀÎÁ¤º¸º¸È£±ÔÁ¤))°ú °°Àº ±ÔÁ¦´Â ÀÇ·á ±â°üÀÌ º¸¾È°ú ȯÀÚÀÇ ÇÁ¶óÀ̹ö½Ã¸¦ À¯ÁöÇϸ鼭 µ¥ÀÌÅÍÀÇ À̵¿¼ºÀ» Çâ»ó½ÃŰ´Â »óÈ£ ¿î¿ë °¡´ÉÇÑ ½Ã½ºÅÛÀ» äÅÃÇϵµ·Ï À¯µµÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇコÄɾ °¡Ä¡ ±â¹Ý Áø·á ¸ðµ¨·Î ÀüȯÇϰí ÀÖ´Â »óȲ¿¡¼­ »óÈ£¿î¿ë¼ºÀº °á°ú¸¦ ÃøÁ¤Çϰí, Ä¡·á °èȹÀ» ÃÖÀûÈ­Çϸç, Æ÷ǽ·¹ÀÌ¼Ç Çコ ÀÌ´Ï¼ÅÆ¼ºê¸¦ Áö¿øÇϱâ À§ÇØ ¿©·¯ ÃâóÀÇ µ¥ÀÌÅ͸¦ ÅëÇÕÇÏ´Â µ¥ ÀÖ¾î ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ȯÀÚ °³ÀÎ ±â·Ï°ú ÅëÇÕµÈ ÇコÄÉ¾î »ýŰ迡 ´ëÇÑ ¿ä±¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó °í±Þ µ¥ÀÌÅÍ »óÈ£¿î¿ë¼º ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

API¿Í AI´Â ÇコÄÉ¾î µ¥ÀÌÅÍÀÇ »óÈ£¿î¿ë¼ºÀ» ¾î¶»°Ô °­È­ÇÒ ¼ö ÀÖÀ»±î?

¾ÖÇø®ÄÉÀÌ¼Ç ÇÁ·Î±×·¡¹Ö ÀÎÅÍÆäÀ̽º(API)¿Í ÀΰøÁö´É(AI)ÀÇ µµÀÔÀº ÇコÄÉ¾î µ¥ÀÌÅÍÀÇ »óÈ£¿î¿ë¼º¿¡ Çõ¸íÀ» ÀÏÀ¸ÄÑ º¸´Ù È¿À²ÀûÀ̰í È®À强ÀÌ ¶Ù¾î³ª¸ç, API´Â ¼­·Î ´Ù¸¥ ÇコÄÉ¾î ½Ã½ºÅÛÀÌ ¿øÈ°ÇÏ°Ô Åë½ÅÇÒ ¼ö ÀÖµµ·Ï ÇÏ¿© º´¿ø, Ŭ¸®´Ð, ¿ø°Ý ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü °£ÀÇ ½Ç½Ã°£ µ¥ÀÌÅÍ ±³È¯À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. AI¸¦ Ȱ¿ëÇÑ »óÈ£¿î¿ë ¼Ö·ç¼ÇÀº ¹æ´ëÇÑ ¾çÀÇ ºñÁ¤Çü ÀÇ·á µ¥ÀÌÅ͸¦ ºÐ¼®Çϰí, ÆÐÅÏÀ» °¨ÁöÇϰí, ±¸Á¶È­µÇ°í Ç¥ÁØÈ­µÈ Çü½ÄÀ¸·Î º¯È¯ÇÒ ¼ö ÀÖ´Â AI ±â¹Ý »óÈ£¿î¿ë ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ÀÚ¿¬¾î ó¸®(NLP)´Â ÀÓ»ó ±â·Ï¿¡¼­ ÅëÂû·ÂÀ» ÃßÃâÇÏ´Â µ¥ »ç¿ëµÇ¸ç, ¼­·Î ´Ù¸¥ EHR ½Ã½ºÅÛ °£¿¡ ´õ ³ªÀº µ¥ÀÌÅÍ ÅëÇÕÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¶ÇÇÑ AI ±â¹Ý »óÈ£¿î¿ë¼º Ç÷§ÆûÀº ºÒÀÏÄ¡¸¦ ½Äº°Çϰí ȯÀÚ ±â·ÏÀÌ ¿ÏÀüÇϰí ÃֽŠ»óÅÂÀÎÁö È®ÀÎÇÏ¿© µ¥ÀÌÅÍÀÇ Á¤È®¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù. ¶ÇÇÑ, Ŭ¶ó¿ìµå ÄÄÇ»ÆÃÀÇ ÅëÇÕÀ¸·Î µ¥ÀÌÅÍ ÀúÀå ¹× °Ë»ö ±â´ÉÀÌ °­È­µÇ¾î º¸¾ÈÀ» À¯ÁöÇϸ鼭 ȯÀÚ ±â·Ï¿¡ ´ëÇÑ ¿ø°Ý ¾×¼¼½º°¡ °¡´ÉÇØÁ³À¸¸ç, AI¿Í ÀÚµ¿È­°¡ ¹ßÀüÇÔ¿¡ µû¶ó ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü´Â ÀÓ»ó ¿öÅ©Ç÷οì¿Í ȯÀÚ Ä¡·á¸¦ °­È­ÇÏ´Â ´õ Áö´ÉÀûÀ̰í ÀÚ°¡ ÇнÀÀÌ °¡´ÉÇÑ »óÈ£¿î¿ë¼º ¼Ö·ç¼ÇÀ» ±â´ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

¿ÏÀüÇÑ µ¥ÀÌÅÍ »óÈ£¿î¿ë¼ºÀ» ´Þ¼ºÇϱâ À§ÇÑ ÁÖ¿ä À庮Àº ¹«¾ùÀΰ¡?

µ¥ÀÌÅÍ »óÈ£¿î¿ë¼ºÀÇ ÀåÁ¡¿¡µµ ºÒ±¸Çϰí, Àϰü¼º ¾ø´Â µ¥ÀÌÅÍ Ç¥ÁØ, º¸¾È ¹®Á¦, ½Ã½ºÅÛ ÅëÇÕ¿¡ ´ëÇÑ ÀúÇ× µî ¸î °¡Áö À庮ÀÌ ³²¾ÆÀÖ½À´Ï´Ù. ¸¹Àº ÇコÄɾî Á¶Á÷Àº ½Ç½Ã°£ µ¥ÀÌÅÍ ±³È¯À» Áö¿øÇÏ´Â ±â¼ú ÀÎÇÁ¶ó°¡ ¾ø´Â ·¹°Å½Ã ½Ã½ºÅÛÀ» »ç¿ëÇϰí ÀÖ½À´Ï´Ù. º¸ÆíÀûÀ¸·Î ¹Þ¾Æµé¿©Áö´Â »óÈ£¿î¿ë¼º Ç¥ÁØÀÌ ¾ø±â ¶§¹®¿¡ µ¥ÀÌÅÍ ½Ã½ºÅÛÀÌ ÆÄÆíÈ­µÇ¾î ¼­·Î Åë½ÅÇÏ´Â µ¥ ¾î·Á¿òÀ» °Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, µ¥ÀÌÅÍ À¯Ãâ ¹× ¹«´Ü ¾×¼¼½º¿Í °°Àº »çÀ̹ö º¸¾È À§ÇèÀº °³¹æÇü µ¥ÀÌÅÍ ±³È¯¿¡ Å« µµÀüÀÌ µÇ°í ÀÖÀ¸¸ç, IT ÀÎÇÁ¶ó ¾÷±×·¹ÀÌµå ¹× »óÈ£¿î¿ë¼º ¼Ö·ç¼Ç µµÀÔ¿¡ µû¸¥ ³ôÀº ºñ¿ëµµ ¼Ò±Ô¸ð ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü¿¡ Å« °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. Àå¾Ö¹°ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿öÅ©Ç÷οìÀÇ È¥¶õ°ú µ¥ÀÌÅÍ Á¤È®¼º¿¡ ´ëÇÑ ¿ì·Á·Î ÀÎÇØ ÀÇ·á Àü¹®°¡µéÀÌ º¯È­¿¡ ´ëÇÑ °ÅºÎ°¨À» °®°í ÀÖ´Â °Íµµ »óÈ£¿î¿ë °¡´ÉÇÑ ½Ã½ºÅÛÀÇ µµÀÔÀ» Áö¿¬½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ À庮À» ±Øº¹Çϱâ À§Çؼ­´Â Á¤ºÎÀÇ Àμ¾Æ¼ºê, ¾÷°è Àü¹ÝÀÇ Çù·Â, ¾ÈÀüÇϰí Ç¥ÁØÈ­µÈ È®Àå °¡´ÉÇÑ »óÈ£¿î¿ë ÇÁ·¹ÀÓ¿öÅ©¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ÅõÀÚ°¡ ÇÊ¿äÇÕ´Ï´Ù.

ÇコÄÉ¾î µ¥ÀÌÅÍ »óÈ£¿î¿ë¼º ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

ÇコÄÉ¾î µ¥ÀÌÅÍ »óÈ£¿î¿ë¼º ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº ±ÔÁ¦ Áؼö Àǹ«È­, µðÁöÅÐ Çコ ¼Ö·ç¼ÇÀÇ È®´ë, ½Ç½Ã°£ µ¥ÀÌÅÍ ¾×¼¼½º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ÀÔ´Ï´Ù. ¿ø°Ý ÀÇ·á¿Í ¿þ¾î·¯ºí ±â±âÀÇ º¸±ÞÀ¸·Î ÀÎÇØ È¿À²ÀûÀ¸·Î ÅëÇÕ ¹× °øÀ¯ÇØ¾ß ÇÏ´Â °Ç°­ µ¥ÀÌÅͰ¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °¡Ä¡ ±â¹Ý ÀÇ·á¿Í ȯÀÚ Á᫐ ÀÇ·á ¸ðµ¨ÀÇ ºÎ»óÀ¸·Î ÀÇ·á ¼­ºñ½º Á¦°ø¾÷üµéÀº ÀÇ·á ¿¬°è¸¦ °³¼±ÇÏ°í ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ´Â »óÈ£¿î¿ë¼º ¼Ö·ç¼ÇÀ» µµÀÔÇϰí ÀÖÀ¸¸ç, AI, ºí·ÏüÀÎ, Ŭ¶ó¿ìµå ÄÄÇ»ÆÃÀÇ ¹ßÀüÀº µ¥ÀÌÅÍ º¸¾È, Á¢±Ù¼º, Ç¥ÁØÈ­¸¦ °­È­ÇÔÀ¸·Î½á µ¥ÀÌÅÍ º¸¾È, Á¢±Ù¼º, Ç¥ÁØÈ­¸¦ °­È­ÇÔÀ¸·Î½á ½ÃÀå ¼ºÀåÀ» ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ÀÇ·á ±â°üÀÌ ¿øÈ°ÇÑ µ¥ÀÌÅÍ ±³È¯¿¡ ´ëÇÑ ¿ì¼±¼øÀ§°¡ ³ô¾ÆÁü¿¡ µû¶ó, °­·ÂÇÑ »óÈ£¿î¿ë¼º ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸ鼭 Ä¿³ØÆ¼µå ÇコÄɾîÀÇ ¹Ì·¡¸¦ Çü¼ºÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

·¹º§(±âÃÊ ·¹º§, ±¸Á¶ ·¹º§, ÀÇ¹Ì ·¹º§);Àü°³(Ŭ¶ó¿ìµå ±â¹Ý Àü°³, On-Premise Àü°³);¸ðµ¨(ÁýÁßÇü ¸ðµ¨, ÇÏÀ̺긮µå ¸ðµ¨, ºÐ»êÇü ¸ðµ¨);¿ëµµ(Áø´Ü ¿ëµµ, Ä¡·á ¿ëµµ, ±âŸ ¿ëµµ);ÃÖÁ¾ ¿ëµµ(¿Ü·¡ ÀÇ·á±â°ü ÃÖÁ¾ ¿ëµµ, º´¿ø ÃÖÁ¾ ¿ëµµ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Healthcare Data Interoperability Market to Reach US$13.1 Billion by 2030

The global market for Healthcare Data Interoperability estimated at US$6.8 Billion in the year 2024, is expected to reach US$13.1 Billion by 2030, growing at a CAGR of 11.5% over the analysis period 2024-2030. Foundational Level, one of the segments analyzed in the report, is expected to record a 12.1% CAGR and reach US$8.7 Billion by the end of the analysis period. Growth in the Structural Level segment is estimated at 9.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.9 Billion While China is Forecast to Grow at 15.6% CAGR

The Healthcare Data Interoperability market in the U.S. is estimated at US$1.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.7 Billion by the year 2030 trailing a CAGR of 15.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.3% and 10.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.1% CAGR.

Global Healthcare Data Interoperability Market - Key Trends & Drivers Summarized

Why Is Data Interoperability a Game Changer in Healthcare?

The ability to seamlessly exchange healthcare data across different platforms and systems has become a critical factor in improving patient outcomes, reducing costs, and enhancing operational efficiency. Healthcare data interoperability enables electronic health records (EHRs), imaging systems, wearables, and laboratory information systems to communicate with one another, ensuring that patient data is accessible across providers, insurers, and research institutions. The lack of interoperability has historically been a significant barrier to coordinated care, often leading to redundant tests, misdiagnoses, and delayed treatments. With the rise of personalized medicine and data-driven healthcare, seamless data exchange is essential for real-time decision-making and predictive analytics. Regulatory mandates, such as the U.S. 21st Century Cures Act and the European Union’s General Data Protection Regulation (GDPR), are pushing healthcare organizations to adopt interoperable systems that enhance data portability while maintaining security and patient privacy. Additionally, as healthcare shifts towards value-based care models, interoperability is crucial in aggregating data from multiple sources to measure outcomes, optimize treatment plans, and support population health initiatives. The growing need for holistic patient records and integrated healthcare ecosystems is fueling demand for advanced data interoperability solutions.

How Are APIs and AI Enhancing Healthcare Data Interoperability?

The adoption of application programming interfaces (APIs) and artificial intelligence (AI) is revolutionizing healthcare data interoperability, making it more efficient and scalable. APIs enable different healthcare systems to communicate seamlessly, allowing real-time data exchange between hospitals, clinics, and telehealth providers. AI-powered interoperability solutions can analyze vast amounts of unstructured health data, detect patterns, and convert them into structured, standardized formats. Natural language processing (NLP) is being used to extract insights from clinical notes, enabling better data integration across different EHR systems. AI-driven interoperability platforms are also improving data accuracy by identifying inconsistencies and ensuring that patient records are complete and up to date. Furthermore, the integration of cloud computing has enhanced data storage and retrieval capabilities, enabling remote access to patient records without compromising security. As AI and automation continue to improve, healthcare providers can expect more intelligent, self-learning interoperability solutions that enhance clinical workflows and patient care.

What Are the Key Barriers to Achieving Full Data Interoperability?

Despite the advantages of data interoperability, several barriers remain, including inconsistent data standards, security concerns, and resistance to system integration. Many healthcare organizations operate on legacy systems that lack the technical infrastructure to support real-time data exchange. The absence of universally accepted interoperability standards results in fragmented data systems that struggle to communicate with each other. Additionally, cybersecurity risks, including data breaches and unauthorized access, pose significant challenges to open data exchange. The high costs associated with upgrading IT infrastructure and implementing interoperability solutions are another hurdle for smaller healthcare providers. Resistance to change among healthcare professionals, due to concerns about workflow disruptions and data accuracy, also slows down the adoption of interoperable systems. Overcoming these barriers requires government incentives, industry-wide collaboration, and continued investment in secure, standardized, and scalable interoperability frameworks.

What Is Driving the Growth of the Healthcare Data Interoperability Market?

The growth in the healthcare data interoperability market is driven by regulatory compliance mandates, the expansion of digital health solutions, and increasing demand for real-time data access. The widespread adoption of telehealth and wearable devices has created a surge in health data that must be integrated and shared efficiently. Additionally, the rise of value-based care and patient-centric healthcare models is pushing providers to adopt interoperability solutions that improve care coordination and reduce costs. Advancements in AI, blockchain, and cloud computing are further accelerating market growth by enhancing data security, accessibility, and standardization. As healthcare organizations continue to prioritize seamless data exchange, the demand for robust interoperability solutions is expected to rise, shaping the future of connected healthcare.

SCOPE OF STUDY:

The report analyzes the Healthcare Data Interoperability market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Level (Foundational Level, Structural Level, Semantic Level); Deployment (Cloud-based Deployment, On-Premise Deployment); Model (Centralized Model, Hybrid Model, Decentralized Model); Application (Diagnosis Application, Treatment Application, Other Applications); End-Use (Ambulatory Care Providers End-Use, Hospitals End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â